person · Reporting owner

Bazan J. Fernando

Disclosed activity across 1 company

Tapewire entity: 172264
SEC CIK: 0001583204

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-TECHNE CorpTECH · Entity 3479	Chief Technical Officer	October 26, 2017	October 30, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-TECHNE Corp

Report date October 26, 2017 · Filed October 30, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,649	Reported balance After 2017-10-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-10-26 · Grant · Acquired 1,649 · Balance 1,649 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,200	Reported balance Holding disclosure · report date 2017-10-26 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance 1,200 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,759	Reported balance Holding disclosure · report date 2017-10-26 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance 1,759 F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09	Direct	9,089	Reported balance After 2017-10-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-10-26 · Grant · Acquired 9,089 · Balance 9,089 F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $125.05 · Expires 2024-08-09	Direct	12,119	Reported balance After 2017-10-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-10-26 · Grant · Acquired 12,119 · Balance 12,119 F3: Vests 3,029 shares on 8/9/2018 and 3,030 shares each on 8/9/2019, 8/9/2020 and 8/9/2021
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18	Direct	14,476	Reported balance Holding disclosure · report date 2017-10-26 · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · Balance 14,476 F8: Vests 3,619 shares on each 8/18/17, 8/18/18, 8/18/19 and 8/18/20.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $106.59 · Expires 2023-08-18	Direct	10,857	Reported balance Holding disclosure · report date 2017-10-26 · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · Balance 10,857 F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $108.49 · Expires 2022-08-07	Direct	10,000	Reported balance Holding disclosure · report date 2017-10-26 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance 10,000 F6: Vests 2,500 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.35 · Expires 2021-08-12	Direct	15,000	Reported balance Holding disclosure · report date 2017-10-26 · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · Balance 15,000 F7: Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.02 · Expires 2020-07-31	Direct	10,000	Reported balance Holding disclosure · report date 2017-10-26 · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · Balance 10,000
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $76.02 · Expires 2020-07-31	Direct	15,000	Reported balance Holding disclosure · report date 2017-10-26 · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · Balance 15,000
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $108.49 · Expires 2022-08-07	Direct	7,500	Reported balance Holding disclosure · report date 2017-10-26 · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · Balance 7,500 F4: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F2: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F3: Vests 3,029 shares on 8/9/2018 and 3,030 shares each on 8/9/2019, 8/9/2020 and 8/9/2021

F4: Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F5: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F6: Vests 2,500 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

F7: Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17 and 8/12/18.

F8: Vests 3,619 shares on each 8/18/17, 8/18/18, 8/18/19 and 8/18/20.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 26, 2017 Filed Oct 30, 2017 21:08 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to buy) · Derivative	12,119	$0.00 Strike: $125.05	$0.00	Disclosure SEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 3 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,119 Underlying: Common Stock · 12,119 shares Expires 2024-08-09 F3 · derivative.exercise_date: Vests 3,029 shares on 8/9/2018 and 3,030 shares each on 8/9/2019, 8/9/2020 and 8/9/2021 Read SEC document
October 26, 2017 Filed Oct 30, 2017 21:08 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantStock Options (Right to buy) · Derivative	9,089	$0.00 Strike: $125.05	$0.00	Disclosure SEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 2 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,089 Underlying: Common Stock · 9,089 shares Expires 2024-08-09 F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document
October 26, 2017 Filed Oct 30, 2017 21:08 UTC	BIO-TECHNE Corp TECH · Entity 3479	GrantRestricted Stock Units · Derivative	1,649	$0.00	$0.00	Disclosure SEC source: 0001562180-17-003384 · primarydocument.xml · derivative · entry 1 Bazan J. Fernando · CIK 0001583204 · Chief Technical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,649 Underlying: Common Stock · 1,649 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.